Nasdaq
$27.82▼ 1.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.99BShares out 71.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 2d agoPre-market26.10.23 19:078-KKey event#●●●#●●●#●●●
Zymeworks Inc.Bullish
Zymeworks has entered into a global license and collaboration agreement with Roche for its DLL3-targeting T-cell engager candidate, ZW209. Under the terms, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development and commercial milestones plus tiered royalties on net sales.…more
$27.82-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:15PRE 14AOther
Zymeworks Inc.
Zymeworks Inc. will hold its 2026 annual meeting of stockholders on December 15, 2026. The meeting agenda includes the election of directors, advisory votes on executive compensation, approval of the 2026 Employee Stock Purchase Plan, declassification of the board of directors, and the ratification of the appointment of auditors.…more
$27.82-1.38%vs prev closeView filingShare - 10.9After-hours26.10.10 07:284Ownership
Zymeworks Inc.
Adam Schayowitz, an executive at Zymeworks Inc., filed a Form 4 on October 9, 2026, to report changes in his beneficial ownership of securities. This filing serves as an official disclosure of insider equity transactions.…more
$27.82-1.38%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoClosed26.10.24 15:30#●●●#●●●#●●●
Zymeworks Reports Positive Phase 1 Data for Ovarian Cancer Candidate ZW191…more
Zymeworks presented Phase 1 clinical data for its ADC candidate ZW191 at ESMO 2026, demonstrating promising anti-tumor activity and a manageable safety profile in ovarian cancer patients. The company intends to advance clinical development through potential strategic partnerships, though further validation remains necessary.…more
$27.82-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 2d agoPre-market26.10.23 19:00
●●●●●●●● ●●●●● ●●●●●●
Zymeworks has entered into a global license and collaboration agreement with Roche to develop the DLL3-targeting cancer therapy ZW209. Under the deal, Zymeworks will receive a $55 million upfront payment and is eligible for up to $718 million in future development and commercial milestones.…more
$27.82-1.38%vs prev close - 6d agoPre-market26.10.19 19:00
●●●●●●●● ●●●●● ●●●●●●
Zymeworks has appointed Suzanne Monahan as the new Senior Vice President and General Manager of its recently acquired subsidiary, Theravance Biopharma. This leadership appointment aims to strengthen the commercial strategy and market growth for the company's COPD treatment, YUPELRI.…more
$27.82-1.38%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report